Avantax Advisory Services Inc. Sells 1,365 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Avantax Advisory Services Inc. trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 23.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,336 shares of the medical research company’s stock after selling 1,365 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Bio-Rad Laboratories were worth $1,424,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth about $342,686,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after acquiring an additional 4,260 shares in the last quarter. Westfield Capital Management Co. LP grew its position in Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock worth $84,571,000 after acquiring an additional 9,584 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Bio-Rad Laboratories in the third quarter worth about $83,681,000. Finally, Charles Schwab Investment Management Inc. grew its position in Bio-Rad Laboratories by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock worth $63,030,000 after acquiring an additional 7,552 shares in the last quarter. 65.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on BIO. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Trading Up 1.2 %

BIO opened at $260.16 on Wednesday. The stock has a market cap of $7.29 billion, a price-to-earnings ratio of -4.00 and a beta of 0.98. The stock’s 50 day moving average price is $308.56 and its 200-day moving average price is $326.91. Bio-Rad Laboratories, Inc. has a one year low of $244.00 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.